Dr. Agarwal's Eye Hospital Limited (BOM:526783)
India · Delayed Price · Currency is INR 5,455.60
-41.35 (-0.75%)
At close: Dec 5, 2025
BOM:526783 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 4,296 | 3,972 | 3,193 | 2,681 | 2,012 | 1,398 | Upgrade |
Other Revenue | - | - | - | - | - | 5.17 | Upgrade |
| 4,296 | 3,972 | 3,193 | 2,681 | 2,012 | 1,403 | Upgrade | |
Revenue Growth (YoY) | 19.70% | 24.38% | 19.10% | 33.24% | 43.39% | -20.85% | Upgrade |
Cost of Revenue | 2,394 | 2,260 | 1,868 | 1,576 | 649.3 | 510.69 | Upgrade |
Gross Profit | 1,902 | 1,712 | 1,325 | 1,105 | 1,363 | 892.57 | Upgrade |
Selling, General & Admin | 147.8 | 147.8 | 127.7 | 106.3 | 71.2 | 49.82 | Upgrade |
Other Operating Expenses | 400.9 | 370.4 | 282.4 | 246.1 | 714.8 | 522.15 | Upgrade |
Operating Expenses | 977 | 919.9 | 678.3 | 556.5 | 989.9 | 774.38 | Upgrade |
Operating Income | 924.7 | 792.1 | 646.8 | 548.3 | 372.9 | 118.19 | Upgrade |
Interest Expense | -135.5 | -123.6 | -71 | -68 | -61.2 | -61.31 | Upgrade |
Interest & Investment Income | 8.2 | 8.2 | 19.5 | 7.8 | 5.4 | 1.32 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | -1.1 | -0.1 | -0.08 | Upgrade |
Other Non Operating Income (Expenses) | -6.3 | 5.7 | 12.3 | 4.3 | 3.9 | -0.59 | Upgrade |
EBT Excluding Unusual Items | 791.1 | 682.4 | 607.6 | 491.3 | 320.9 | 57.53 | Upgrade |
Gain (Loss) on Sale of Investments | 8.8 | 8.8 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -1.6 | -1.6 | -2.3 | 0.3 | 2.2 | -0.2 | Upgrade |
Other Unusual Items | 17.4 | 17.4 | 17.2 | 2.4 | - | - | Upgrade |
Pretax Income | 815.7 | 707 | 622.5 | 494 | 323.1 | 57.33 | Upgrade |
Income Tax Expense | 186 | 160.5 | 158.9 | 124.8 | 82.1 | 71.71 | Upgrade |
Net Income | 629.7 | 546.5 | 463.6 | 369.2 | 241 | -14.39 | Upgrade |
Net Income to Common | 629.7 | 546.5 | 463.6 | 369.2 | 241 | -14.39 | Upgrade |
Net Income Growth | 24.72% | 17.88% | 25.57% | 53.20% | - | - | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
EPS (Basic) | 133.92 | 116.28 | 98.64 | 78.55 | 51.28 | -3.06 | Upgrade |
EPS (Diluted) | 133.92 | 116.28 | 98.64 | 78.55 | 51.28 | -3.06 | Upgrade |
EPS Growth | 24.66% | 17.88% | 25.57% | 53.19% | - | - | Upgrade |
Free Cash Flow | 137.3 | -83.8 | 184.5 | -7.2 | 99.5 | 226.91 | Upgrade |
Free Cash Flow Per Share | 29.20 | -17.83 | 39.26 | -1.53 | 21.17 | 48.28 | Upgrade |
Dividend Per Share | 6.500 | 6.000 | 5.000 | 3.000 | 3.000 | - | Upgrade |
Dividend Growth | 30.00% | 20.00% | 66.67% | - | - | - | Upgrade |
Gross Margin | 44.27% | 43.11% | 41.50% | 41.21% | 67.73% | 63.61% | Upgrade |
Operating Margin | 21.53% | 19.95% | 20.26% | 20.45% | 18.53% | 8.42% | Upgrade |
Profit Margin | 14.66% | 13.76% | 14.52% | 13.77% | 11.98% | -1.03% | Upgrade |
Free Cash Flow Margin | 3.20% | -2.11% | 5.78% | -0.27% | 4.95% | 16.17% | Upgrade |
EBITDA | 1,179 | 1,020 | 779.5 | 643.8 | 489 | 226.98 | Upgrade |
EBITDA Margin | 27.45% | 25.68% | 24.41% | 24.01% | 24.30% | 16.18% | Upgrade |
D&A For EBITDA | 254.5 | 227.9 | 132.7 | 95.5 | 116.1 | 108.79 | Upgrade |
EBIT | 924.7 | 792.1 | 646.8 | 548.3 | 372.9 | 118.19 | Upgrade |
EBIT Margin | 21.53% | 19.95% | 20.26% | 20.45% | 18.53% | 8.42% | Upgrade |
Effective Tax Rate | 22.80% | 22.70% | 25.53% | 25.26% | 25.41% | 125.09% | Upgrade |
Revenue as Reported | 4,335 | 4,022 | 3,243 | 2,697 | 2,025 | 1,406 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.